Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Sales and Divestitures: 2015-2025

Historic Gains from Sales and Divestitures for Seres Therapeutics (MCRB) over the last 9 years, with Sep 2025 value amounting to $52,160.

  • Seres Therapeutics' Gains from Sales and Divestitures fell 96.29% to $52,160 in Q3 2025 from the same period last year, while for Sep 2025 it was $52,160, marking a year-over-year decrease of 96.29%. This contributed to the annual value of $2.2 million for FY2024, which is 44.01% up from last year.
  • Per Seres Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $52,160 for Q3 2025, which was up 48.35% from $35,161 recorded in Q2 2025.
  • Seres Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $2.2 million during Q4 2024, with a 5-year trough of $650 in Q1 2021.
  • In the last 3 years, Seres Therapeutics' Gains from Sales and Divestitures had a median value of $436,652 in 2023 and averaged $665,016.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 99.48% in 2021, then soared by 26,184.00% in 2022.
  • Over the past 5 years, Seres Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $650 in 2021, then spiked by 26,184.00% to $282,401 in 2022, then spiked by 439.89% to $1.5 million in 2023, then skyrocketed by 44.01% to $2.2 million in 2024, then slumped by 96.29% to $52,160 in 2025.
  • Its last three reported values are $52,160 in Q3 2025, $35,161 for Q2 2025, and $12,966 during Q1 2025.